The efficacy of administering elbasvir/grazoprevir as hepatitis C therapy in hemodialysis patients with comorbid of hypertension and diabetes mellitus

Abstract

Background: Hepatitis C and chronic kidney disease (CKD) are significant global health burdens. Hemodialysis therapy can pose a risk of hepatitis C infection. Conditions related to Hepatitis C, such as hypertension and diabetes, have morbidity and mortality rates and can impact the outcomes of hepatitis C treatment. Objective: This study aimed to assess the efficacy of Elbasvir/Grazoprevir as hepatitis C therapy in hemodialysis patients with comorbid hypertension and diabetes mellitus. Methods: The target population for this study consists of hepatitis C-infected patients undergoing routine hemodialysis with comorbid hypertension and diabetes mellitus who were treated with Elbasvir/Grazoprevir. The data collected included demographic characteristics, comorbid conditions (hypertension and diabetes mellitus), cirrhosis status, and whether patients achieved Sustained Virologic Response (SVR). Multinomial logistic regression was used to calculate the odds ratio (OR). Results: From the population profile of the study, a total of 164 individuals were included, with the majority being under 60 years old. Patients with comorbid hypertension or diabetes mellitus achieved SVR rates of 95% and 83.3%, respectively, while patients with both comorbid conditions, hypertension, and diabetes mellitus, had an SVR rate of 74.07%. The multinomial logistic regression analysis showed that patients with both comorbid conditions (HT and DM) had a higher risk of failing to achieve SVR compared to patients without comorbid conditions, with an OR of 22.4, p = 0.005. Conclusion: Administering Elbasvir/Grazoprevir for hepatitis C therapy in hemodialysis patients with comorbid hypertension and/or diabetes mellitus carries a higher risk of SVR failure compared to those without comorbid conditions.